secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040590
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic
--------------------------------------------------------------------------------

- Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.
- Cash, cash equivalents and marketable securities $59.8M as of June 30, 2023; projected to fund ops through Q3 2024.
- Herpesvirus candidate ABI-5366 entered GLP toxicology; IND/CTA submission planned for H1 2024.
- Second development candidate nomination expected in 2023; additional candidate to enter clinic by year-end 2024.
- Three abstracts accepted for 2023 International HBV Meeting in Kobe, Japan (Sept 19-23).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/0000950170-23-040590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/asmb-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer